[
    [
        {
            "time": "2018-06-15",
            "original_text": "Gilead's (GILD) Harvoni and Descovy Get Approval in China",
            "features": {
                "keywords": [
                    "Harvoni",
                    "Descovy",
                    "approval",
                    "China"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Gilead's (GILD) Harvoni and Descovy Get Approval in China",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-04",
            "original_text": "AbbVie halts late-stage trial for lung cancer drug Rova-T",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Rova-T",
                    "halted",
                    "trial"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie halts late-stage trial for lung cancer drug Rova-T",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-20",
            "original_text": "Why Oregon can now afford to treat more people with hepatitis C",
            "features": {
                "keywords": [
                    "Oregon",
                    "hepatitis C",
                    "treatment",
                    "afford"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Why Oregon can now afford to treat more people with hepatitis C",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-12",
            "original_text": "Wall Street Is Souring on These 7 Stocks to Sell",
            "features": {
                "keywords": [
                    "Wall Street",
                    "souring",
                    "stocks",
                    "sell"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Wall Street Is Souring on These 7 Stocks to Sell",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-04",
            "original_text": "Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted",
            "features": {
                "keywords": [
                    "Phase 3",
                    "Rova-T",
                    "halted",
                    "trial"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-05",
            "original_text": "7 Dividend Aristocrats to Buy for 2019",
            "features": {
                "keywords": [
                    "Dividend Aristocrats",
                    "buy",
                    "2019"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "7 Dividend Aristocrats to Buy for 2019",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-08-10",
            "original_text": "J&J's Blood Cancer Drugs Succeed in Label Expansion Studies",
            "features": {
                "keywords": [
                    "J&J",
                    "Blood Cancer",
                    "Drugs",
                    "Succeed",
                    "Label Expansion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "J&J's Blood Cancer Drugs Succeed in Label Expansion Studies",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "Timely Ten- Top Values from IQ Trends",
            "features": {
                "keywords": [
                    "Timely Ten",
                    "Top Values",
                    "IQ Trends"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Timely Ten- Top Values from IQ Trends",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 3,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]